Default

Allergy and immunology

Anaesthesia

Basic research

Cardiovascular medicine

Complementary medicine and alternative therapies

Critical care / intensive care

Dentistry / oral medicine

Dermatology

Emergency medicine

Endocrinology

Epidemiology

Ethics

Evidence-based medicine

Gastroenterology

Genetics

Geriatric medicine / aging

Haematology / blood transfusion

Health economics

Health policy

History of medicine

Infectious diseases

Internal medicine

Laboratory medicine

Medical education

Medical informatics

Neurology

Nursing

Nutrition and metabolism

Obstetrics and gynaecology

Occupational and environmental medicine

Oncology

Ophthalmology

Organisation of health care

Otolaryngology / head and neck surgery

Paediatrics

Palliative care

Pathology

Patient-physician relationship

Pharmacology and therapeutics

Primary care, family medicine

Psychiatry and psychotherapy

Psychosomatics

Public health

Quality of care

Radiology

Rehabilitation medicine

Renal medicine

Respiratory medicine

Rheumatology

Sexual medicine

Sports medicine

Statistics and research methods

Surgery

Transplantation

Travel medicine

Urology

Ops! No article found. Reset filter

Stroke management in a Swiss community hospital – in close collaboration with a stroke centre

Original article
Erlebach R, Bächli E, Gerrits E, Hess M
Swiss Med Wkly. 2021;151:w20490

Despite the universal recognition that stroke is a major burden of public health in developed countries, little is known concerning its epidemiology and care outside of stroke centres. The objective of this study was to provide information concerning risk factors for stroke, stroke management and quality of care in a community hospital in Switzerland. The findings support further education of the population in recognition of stroke symptoms and assessment of cardiovascular risk factors according to guidelines. Telemedical cooperation with a local stroke centre can result in adequate quality of care in these patients.

Fitness-to-drive for glioblastoma patients: Guidance from the Swiss Neuro-Oncology Society (SwissNOS) and the Swiss Society for Legal Medicine (SGRM)

Original article
Hofer S, Keller K, Imbach L, Roelcke U, Hutter G, Hundsberger T, Hertler C, Le Rhun E, Vasella F, Cordier D, Neidert M, Hottinger A, Migliorini D, Pflugshaupt T, Eggenberger N, Baumert B, Läubli H, Gramatzki D, Reinert M, Pesce G, Schucht P, Frank I, Lehnick D, Weiss T, Wirsching HG, Wolpert F, Roth P, Weller M
Swiss Med Wkly. 2021;151:w20501

The management of brain tumour patients who would like to resume driving is complex, and needs multidisciplinary input and a consensus among treating physicians. The Swiss Neuro-Oncology Society (SwissNOS) and the Swiss Society for Legal Medicine (SGRM) aim to provide guidance on how to assess “fitness-to-drive” of glioblastoma patients and to harmonise the relevant procedures in Switzerland.

Early advance care planning in amyotrophic lateral sclerosis patients: results of a systematic intervention by a palliative care team in a multidisciplinary management programme – a 4-year cohort study

Original article
Sukockienė E, Iancu Ferfoglia R, Boegli M, Lefranc Barranco C, Truffert A, Héritier Barras AC, Genton L, Leuchter I, Adler D, Janssens JP, Escher M
Swiss Med Wkly. 2021;151:w20484

Early initiation of advance care planning is feasible in most ALS patients during a routine consultation, and relevant treatment issues can be discussed. All ALS patients should be offered the opportunity to write advance directives as completion was not associated with disease severity.

Continuous versus routine EEG in critically ill adults: reimbursement analysis of a randomised trial

Original article
Urbano V, Novy J, Schindler K, Rüegg S, Alvarez V, Zubler F, Oddo M, Lee JW, Rossetti AO
Swiss Med Wkly. 2021;151:w20477

In a Swiss Diagnosis Related Groups billing system applied to critically ill adults, reimbursement largely depends on duration of acute hospital stay, whereas continuous EEG and lack of seizure/ status epilepticus detection also contribute to the bill. This differs from the USA, where charges are directly increased by continuous EEG.

Characterisation of advanced Parkinson’s disease: OBSERVE-PD observational study – results of the Swiss subgroup

Original article
Möller JC, Baumann CR, Burkhard PR, Kaelin-Lang A, Küng I, Onuk K, Bohlhalter S
Swiss Med Wkly. 2021;151:w20419

Currently, the characterisation of advanced Parkinson’s disease does not follow standardised diagnostic criteria, which complicates the evaluation of ongoing care and treatment strategies, such as eligibility for device-aided treatment. Therefore, this study aimed to determine the proportion of advanced and non-advanced Parkinson’s disease patients treated at specialised movement disorder centres in Switzerland, to compare clinical characteristics and to assess eligibility for and use of device-aided treatment.

Expert recommendation from the Swiss Amyloidosis Network (SAN) for systemic AL-amyloidosis

Review article: Medical guidelines
Schwotzer R, Flammer AJ, Gerull S, Pabst T, Arosio P, Averaimo M, Bacher VU, Bode P, Cavalli A, Concoluci A, Dirnhofer S, Djerbi N, Dobner SW, Fehr T, Garofalo M, Gaspert A, Heimgartner R, Hübers A, Jung HH, Kessler C, Knöpfel R, Laptseva N, Manka R, Mazzucchelli L, Meyer M, Mihaylova V, Monney P, Mylonas A, Nkoulou R, Pazhenkottil A, Pfister O, Rüfer A, Schmidt A, Seeger H, Stämpfli SF, Stirnimann G, Suter T, Théaudin M, Treglia G, Tzankov A, Vetter F, Zweier M, Gerber B
Swiss Med Wkly. 2020;150:w20364

These are the Swiss Amyloidosis Network recommendations which focus on diagnostic work-up and treatment of AL-amyloidosis. One aim of this meeting was to establish a consensus guideline regarding the diagnostic work-up and the treatment recommendations for systemic amyloidosis tailored to the Swiss health care system.

Conference report: dementia research and care and its impact in Switzerland

Special article
Leyhe T, Jucker M, Nef T, Sollberger M, Riese F, Haba-Rubio J, Verloo H, Lüthi R, Becker S, Popp J
Swiss Med Wkly. 2020;150:w20376

A Swiss panel of experts met for the Dementia Summit in Brunnen, Switzerland, to discuss the latest scientific findings on basic and clinical research, as well as practical and political approaches to the challenges of dementia disorders in Switzerland. Here, they present the conference summary.

Immune checkpoint inhibitor therapy-associated encephalitis: a case series and review of the literature

Original article
Stuby J, Herren T, Schwegler Naumburger G, Papet C, Rudiger A
Swiss Med Wkly. 2020;150:w20377

Encephalitis should be suspected in patients treated with immune checkpoint inhibitors who present with rapidly evolving confusion. Blood tests, CSF analysis, cerebral MRI and an EEG should be performed. Therapy with intravenous corticosteroids is recommended. Steroid unresponsiveness is rare and should lead to a review of the diagnosis. Alternative treatment options are IVIG, plasma exchange therapy and rituximab.

Multisystem inflammatory syndrome with refractory cardiogenic shock due to acute myocarditis and mononeuritis multiplex after SARS-CoV-2 infection in an adult

Original article
Othenin-Girard A, Regamey J, Lamoth F, Horisberger A, Glampedakis E, Epiney JB, Kuntzer T, de Leval L, Carballares M, Hurni CA, Rusca M, Pantet O, Di Bernardo S, Oddo M, Comte D, Piquilloud L
Swiss Med Wkly. 2020;150:w20387

Multisystem inflammatory syndrome associated with SARS-CoV-2 can occur in adults. The clinical presentation can include severe organ damage with features of incomplete or complete Kawasaki disease, including coronary aneurysm, as well as myocarditis-associated cardiogenic shock and also mononeuritis multiplex.

Outcomes after spinal stenosis surgery by type of surgery in adults aged 60 years and older

Original article
Degen T, Fischer K, Theiler R, Schären S, Meyer OW, Wanner G, Chocano-Bedoya P, Simmen HP, Schmid UD, Steurer J, Stähelin HB, Mantegazza N, Bischoff-Ferrari HA
Swiss Med Wkly. 2020;150:w20325

Verpassen Sie keinen Artikel!

close